Aditxt

Aditxt Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Aditxt (ADTX) as of Nov 3, 2026 is -914,646.85. In the previous year, Cash Conversion Cycle (CCC) was -5,804.11 — a change of 15,658.62% (lower).

Cash Conversion Cycle

-914,646.85

YoY

15,658.62%

Last updated:

Cash Conversion Cycle (CCC) of Aditxt is 2025 -914,646.85 . Cash Conversion Cycle (CCC) of Aditxt was 2024 -5,804.11 . It decreases by 15,658.62% lower compared to the previous year.

The Aditxt Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2020
-4,961.95 USD
Jan 1, 2021
-4,746.41 USD
Jan 1, 2022
-272.84 USD
Jan 1, 2023
-3,535.28 USD
Jan 1, 2024
-5,804.11 USD
Jan 1, 2025
-914,646.85 USD
The Aditxt Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-914,646.85+15,658.62%
-5,804.11+64.18%
-3,535.28+1,195.75%
-272.84-94.25%
-4,746.41-4.34%
-4,961.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Cash Conversion Cycle (CCC) of Aditxt is -914,646.85 in 2025.

Cash Conversion Cycle (CCC) of Aditxt changed from -5,804.11 to -914,646.85, representing a 15,658.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Aditxt since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Aditxt with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Aditxt

All Key Metrics — Aditxt